Cephalon/Cima Merger Contingent On Granting Generic Actiq License To Barr
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr's generic version of Actiq would enter the market when FDA approves Cima's fentanyl product, but no later than February 2007. The companies expect the merger to close in the next few days.
You may also be interested in...
Cephalon Receives “Approvable” Letter For Fentora
The company says it will respond to FDA by the end of July; additional safety and efficacy data are not required for the fentanyl buccal tablet.
Cephalon Receives “Approvable” Letter For Fentora
The company says it will respond to FDA by the end of July; additional safety and efficacy data are not required for the fentanyl buccal tablet.
Cephalon And Barr Reach Patent Settlements For Provigil, Actiq
Barr could gain up to two months of exclusivity for its Actiq generic.